Hitting the target in IDH2 mutant AML

被引：3
|
作者：
Wouters, Bas J. [1 ]
机构：
[1] Erasmus Univ, Med Ctr, Rotterdam, Netherlands
来源：
BLOOD | 2017年 / 130卷 / 06期
关键词：
DIFFERENTIATION; LEUKEMIA; CELLS;
D O I：
10.1182/blood-2017-06-790394
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In this issue of Blood, Stein et al(1) demonstrate the feasibility and clinical efficacy of targeted inhibition of mutant isocitrate dehydrogenase 2 (IDH2) in patients with acute myeloid leukemia (AML). In a related paper, Amatangelo et al(2) investigate mechanisms of response in samples derived from the same patients.
引用
收藏
页码：693 / 694
页数：2
相关论文
共 50 条
  • [1] IDH2 inhibition in AML
    Stein, Eytan M.
    BLOOD, 2023, 141 (15) : 1896 - 1896
  • [2] IDH2 inhibition in AML
    Stein, Eytan M.
    BLOOD, 2023, 141 (02) : 124 - 125
  • [3] A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML
    L M Kats
    S J Vervoort
    R Cole
    A J Rogers
    G P Gregory
    E Vidacs
    J Li
    R Nagaraja
    K E Yen
    R W Johnstone
    Leukemia, 2017, 31 : 1466 - 1470
  • [4] A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML
    Kats, L. M.
    Vervoort, S. J.
    Cole, R.
    Rogers, A. J.
    Gregory, G. P.
    Vidacs, E.
    Li, J.
    Nagaraja, R.
    Yen, K. E.
    Johnstone, R. W.
    LEUKEMIA, 2017, 31 (06) : 1466 - 1470
  • [5] Inhibitors of mutant IDH1 and IDH2
    Pamela Feliciano
    Nature Genetics, 2013, 45 (5) : 477 - 477
  • [6] Induction of sarcomas by mutant IDH2
    Lu, Chao
    Venneti, Sriram
    Akalin, Altuna
    Fang, Fang
    Ward, Patrick S.
    DeMatteo, Raymond G.
    Intlekofer, Andrew M.
    Chen, Chong
    Ye, Jiangbin
    Hameed, Meera
    Nafa, Khedoudja
    Agaram, Narasimhan P.
    Cross, Justin R.
    Khanin, Raya
    Mason, Christopher E.
    Healey, John H.
    Lowe, Scott W.
    Schwartz, Gary K.
    Melnick, Ari
    Thompson, Craig B.
    GENES & DEVELOPMENT, 2013, 27 (18) : 1986 - 1998
  • [7] IDH2 inhibition in AML: Finally progress?
    Stein, Eytan M.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2015, 28 (2-3) : 112 - 115
  • [8] Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells
    Chen, Dong
    Xia, Siyuan
    Zhang, Rukang
    Li, Yuancheng
    Famulare, Christopher A.
    Fan, Hao
    Wu, Rong
    Wang, Mei
    Zhu, Allen C.
    Elf, Shannon E.
    Su, Rui
    Dong, Lei
    Arellano, Martha
    Blum, William G.
    Mao, Hui
    Lonial, Sagar
    Stock, Wendy
    Odenike, Olatoyosi
    Le Beau, Michelle
    Boggon, Titus J.
    He, Chuan
    Chen, Jianjun
    Gao, Xue
    Levine, Ross L.
    Chen, Jing
    MOLECULAR CELL, 2021, 81 (18) : 3833 - +
  • [9] Outcome of AML patients with IDH2 mutations in real world before the era of IDH2 inhibitors
    Largeaud, Laetitia
    Berard, Emilie
    Bertoli, Sarah
    Dufrechou, Stephanie
    Prade, Nais
    Gadaud, Noemie
    Tavitian, Suzanne
    Bories, Pierre
    Luquet, Isabelle
    Sarry, Audrey
    De Mas, Veronique
    Huguet, Francoise
    Delabesse, Eric
    Recher, Christian
    LEUKEMIA RESEARCH, 2019, 81 : 82 - 87
  • [10] Structural Biology of Mutant IDH2 Inhibition
    DeLaBarre, B.
    Wang, F.
    Travins, J.
    Gross, S.
    Artin, E.
    Dang, L.
    Biller, S.
    Yen, K.
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2014, 70 : C799 - C799
12345